Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
China · Delayed Price · Currency is CNY 24.06
-0.53 (-2.16%)
Jul 30, 2026, 9:25 AM CST
SHE:002940 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,718 | 6,574 | 2,632 | 4,377 | 3,684 | 3,486 | |
Market Cap Growth | -60.11% | 149.74% | -39.86% | 18.80% | 5.68% | -12.16% |
Enterprise Value | 4,645 | 6,484 | 2,582 | 4,255 | 3,430 | 2,877 |
Last Close Price | 24.06 | 33.34 | 13.04 | 21.18 | 18.02 | 16.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 38.15 | 52.40 | 32.77 | 31.63 | 28.94 | 29.09 |
PS Ratio | 3.32 | 4.61 | 1.71 | 2.70 | 2.35 | 2.53 |
PB Ratio | 2.49 | 3.52 | 1.46 | 2.39 | 2.24 | 2.36 |
P/TBV Ratio | 3.89 | 5.52 | 2.43 | 3.86 | 2.56 | 2.73 |
P/FCF Ratio | 30.28 | 33.85 | 16.54 | 28.80 | 31.78 | 31.59 |
P/OCF Ratio | 23.64 | 26.93 | 10.38 | 15.81 | 19.94 | 17.64 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.27 | 4.55 | 1.68 | 2.63 | 2.19 | 2.08 |
EV/EBITDA Ratio | 20.38 | 28.32 | 12.56 | 17.65 | 16.91 | 14.56 |
EV/EBIT Ratio | 30.20 | 42.61 | 21.81 | 26.00 | 24.19 | 19.02 |
EV/FCF Ratio | 29.81 | 33.39 | 16.23 | 28.00 | 29.59 | 26.07 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.30 | 0.24 | 0.27 | 0.32 | 0.21 | 0.00 |
Debt / EBITDA Ratio | 2.51 | 1.98 | 2.37 | 2.43 | 1.71 | 0.01 |
Debt / FCF Ratio | 3.67 | 2.34 | 3.06 | 3.88 | 2.99 | 0.02 |
Net Debt / Equity Ratio | -0.17 | -0.18 | -0.14 | -0.15 | -0.28 | -0.51 |
Net Debt / EBITDA Ratio | -1.40 | -1.46 | -1.20 | -1.16 | -2.26 | -3.78 |
Net Debt / FCF Ratio | -2.05 | -1.73 | -1.55 | -1.84 | -3.95 | -6.77 |
Asset Turnover | 0.47 | 0.48 | 0.51 | 0.58 | 0.67 | 0.69 |
Inventory Turnover | 1.79 | 1.82 | 2.06 | 2.66 | 2.28 | 1.74 |
Quick Ratio | 1.24 | 1.25 | 1.16 | 1.55 | 1.40 | 1.79 |
Current Ratio | 1.84 | 1.83 | 1.78 | 2.13 | 1.84 | 2.31 |
Return on Equity (ROE) | 8.35% | 8.55% | 8.37% | 10.53% | 8.46% | 9.91% |
Return on Assets (ROA) | 3.19% | 3.21% | 2.47% | 3.64% | 3.79% | 4.70% |
Return on Invested Capital (ROIC) | 8.63% | 8.58% | 7.31% | 10.55% | 13.29% | 19.59% |
Return on Capital Employed (ROCE) | 7.00% | 7.10% | 5.60% | 7.20% | 7.80% | 10.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.70% | 1.91% | 3.05% | 3.16% | 3.46% | 3.44% |
FCF Yield | 3.30% | 2.95% | 6.05% | 3.47% | 3.15% | 3.16% |
Dividend Yield | 1.22% | 0.75% | 0.96% | 0.99% | 1.15% | 0.86% |
Payout Ratio | 39.64% | 45.92% | 73.15% | 44.53% | 26.83% | 39.27% |
Buyback Yield / Dilution | -0.75% | -0.74% | -0.15% | -0.82% | 0.42% | -5.03% |
Total Shareholder Return | 0.47% | 0.01% | 0.81% | 0.17% | 1.57% | -4.17% |